Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias

J Med Chem. 2019 May 23;62(10):5111-5131. doi: 10.1021/acs.jmedchem.9b00349. Epub 2019 May 13.

Abstract

Starting from the β-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different chemotypes of agonist/antagonist hybrids. Investigations of ligand-mediated receptor activation using bioluminescence resonance energy transfer biosensors revealed a predominant effect of the aromatic head group on the intrinsic activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity. Ligands composed of a catechol head group and an antagonist-like oxypropylene spacer possess significant intrinsic activity for the activation of Gαs, while they only show weak or even no β-arrestin-2 recruitment at both β1- and β2-AR. Molecular dynamics simulations suggest that the difference in G protein efficacy and β-arrestin recruitment of the hybrid ( S)-22, the full agonist epinephrine, and the β2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / chemistry*
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / chemistry*
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Carvedilol / chemical synthesis
  • Carvedilol / chemistry
  • Catechols / chemistry
  • Drug Design
  • GTP-Binding Proteins / drug effects*
  • Humans
  • Hydrogen Bonding
  • Indicators and Reagents
  • Isoproterenol / chemical synthesis
  • Isoproterenol / chemistry
  • Ligands
  • Mice
  • Models, Molecular
  • Molecular Dynamics Simulation
  • Salmeterol Xinafoate / pharmacology
  • beta-Arrestins / drug effects
  • beta-Arrestins / metabolism

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Catechols
  • Indicators and Reagents
  • Ligands
  • beta-Arrestins
  • Carvedilol
  • Salmeterol Xinafoate
  • GTP-Binding Proteins
  • Isoproterenol

Grants and funding